Azenta, Inc. · NASDAQ (us_market)
Healthcare · Medical Instruments & Supplies · United States
Azenta, Inc. provides biological and chemical compound sample exploration and management solutions for the life sciences industry in the United States, China, the United Kingdom, rest of Europe, the Asia Pacific, and internationally. It operates through Sample Management Solutions and Multiomics segments. The Sample Management Solutions segment provides sample management products and services, including automated stores, cryogenic systems, automated sample tubes, consumables and instruments, and controlled rate thawing devices, as well as sample repository services. This segment also offers consultation services to clients throughout their experimental design and implementation processes. The Multiomics segment provides genomic and other sample analysis services comprising gene sequencing, gene synthesis, and related services. The company has a strategic partnership with Frontier Space Ltd to conduct scientific experiments in space. The company was formerly known as Brooks Automation, Inc. and changed its name to Azenta, Inc. in December 2021. Azenta, Inc. was founded in 1978 and is headquartered in Burlington, Massachusetts.
| Event Period | Drawdown | Buy Point (Bottom) | Sell Point (Peak) | ticker.setupCols.buyScore | ticker.setupCols.sellScore | Max Return | Algo Return |
|---|---|---|---|---|---|---|---|
DROP2026-01-22$41.01 RISE2026-05-15$16.02 PEAK2026-05-29$22.88 127d | -60.9% 113d | Missed | Missed | — | — | +42.8% 14d | Missed |
DROP2026-01-22$41.01 RISE2026-03-27$19.90 PEAK2026-04-22$26.46 90d | -51.5% 64d | Missed | Missed | — | — | +33.0% 26d | Missed |
DROP2025-07-23$34.48 RISE2025-09-29$28.17 PEAK2025-11-25$38.10 125d | -18.3% 68d | Missed | Missed | — | — | +35.3% 57d | Missed |
DROP2025-03-26$36.41 RISE2025-08-05$26.90 PEAK2025-10-03$32.45 191d | -26.1% 132d | Missed | Missed | — | — | +20.6% 59d | Missed |
DROP2025-01-23$54.75 RISE2025-04-21$25.03 PEAK2025-07-10$34.15 168d | -54.3% 88d | Missed | Missed | — | — | +36.4% 80d | Missed |
DROP2024-07-31$62.29 RISE2024-11-18$40.37 PEAK2025-01-23$54.75 176d | -35.2% 110d | Missed | Missed | — | — | +35.6% 66d | Missed |
DROP2024-03-01$67.30 RISE2024-07-10$50.53 PEAK2024-07-31$62.29 152d | -24.9% 131d | Missed | Missed | — | — | +23.3% 21d | Missed |
DROP2024-01-29$67.51 RISE2024-05-23$50.27 PEAK2024-07-31$62.29 184d | -25.5% 115d | Missed | Missed | — | — | +23.9% 69d | Missed |
DROP2023-08-09$57.76 RISE2023-10-30$44.02 PEAK2024-01-19$67.41 163d | -23.8% 82d | Missed | Missed | — | — | +53.1% 81d | Missed |
DROP2023-08-09$57.76 RISE2023-09-26$47.90 PEAK2023-12-19$63.82 132d | -17.1% 48d | Missed | Missed | — | — | +33.2% 84d | Missed |
DROP2023-01-10$61.95 RISE2023-05-10$36.45 PEAK2023-07-12$49.37 183d | -41.2% 120d | Missed | Missed | — | — | +35.4% 63d | Missed |
DROP2022-12-02$62.07 RISE2023-03-17$39.51 PEAK2023-06-12$46.44 192d | -36.3% 105d | Missed | Missed | — | — | +17.5% 87d | Missed |
DROP2022-06-02$77.55 RISE2022-10-11$38.60 PEAK2022-12-02$62.07 183d | -50.2% 131d | Missed | Missed | — | — | +60.8% 52d | Missed |
DROP2022-01-03$103.81 RISE2022-05-09$64.69 PEAK2022-05-27$77.77 144d | -37.7% 126d | Missed | Missed | — | — | +20.2% 18d | Missed |
DROP2021-11-08$124.15 RISE2022-03-14$76.30 PEAK2022-03-29$88.55 141d | -38.5% 126d | Missed | Missed | — | — | +16.1% 15d | Missed |
1–15 / 22 1 / 2 | |||||||
Over the last 7 days, the United States market has risen by 1.3%, contributing to a notable 28% climb over the past year, with earnings expected to grow by 17% annually. In this context of robust market performance, identifying stocks that are both undervalued and have significant insider buying can be an effective strategy for investors seeking opportunities in small-cap companies.
Over the last 7 days, the United States market has risen by 1.3%, contributing to a notable 28% climb over the past year, with earnings expected to grow by 17% annually. In this context of robust market performance, identifying stocks that are both undervalued and have significant insider buying can be an effective strategy for investors seeking opportunities in small-cap companies.
Looking back on drug development inputs & services stocks’ Q1 earnings, we examine this quarter’s best and worst performers, including Azenta (NASDAQ:AZTA) and its peers.
Looking back on drug development inputs & services stocks’ Q1 earnings, we examine this quarter’s best and worst performers, including Azenta (NASDAQ:AZTA) and its peers.
Azenta, Inc. (Nasdaq: AZTA) today announced the publication of its annual Environmental, Social, & Governance ("ESG") report, demonstrating continued progress against its key ESG priorities. The report includes ESG data for the Company's fiscal year ended September 30, 2025.
The Russell 2000 (^RUT) is packed with potential breakout stocks, thanks to its focus on smaller companies with high growth potential. However, smaller size also means these businesses often lack the resilience and financial flexibility of large-cap firms, making careful selection crucial.
The Russell 2000 (^RUT) is packed with potential breakout stocks, thanks to its focus on smaller companies with high growth potential. However, smaller size also means these businesses often lack the resilience and financial flexibility of large-cap firms, making careful selection crucial.
Azenta’s first quarter was marked by operational challenges and a more cautious demand environment, which contributed to results well below market expectations. CEO John Marotta acknowledged, “We are not satisfied with our second quarter results,” citing both internal execution gaps and continued customer spending constraints, especially in North America. Management attributed the revenue shortfall largely to softer demand across Multiomics, competitive pressures, and delays in capital equipment
Azenta’s first quarter was marked by operational challenges and a more cautious demand environment, which contributed to results well below market expectations. CEO John Marotta acknowledged, “We are not satisfied with our second quarter results,” citing both internal execution gaps and continued customer spending constraints, especially in North America. Management attributed the revenue shortfall largely to softer demand across Multiomics, competitive pressures, and delays in capital equipment
More than 1,500 stocks have reported earnings since the current season began, and the average stock that's reported has seen an average absolute one-day share price reaction of roughly 7%.
Moby summary of Azenta, Inc.'s Q2 2026 earnings call
Moby summary of Azenta, Inc.'s Q2 2026 earnings call
Needham analyst David Saxon maintains Azenta (NASDAQ:AZTA) with a Buy and lowers the price target from $44 to $33.
Azenta (NASDAQ:AZTA) reported fiscal second-quarter 2026 results that management said fell short of expectations, citing execution shortfalls and a cautious demand environment—particularly in North America—along with ongoing weakness in capital equipment spending. “Candidly, we are not satisfied wi
Azenta (NASDAQ:AZTA) reported fiscal second-quarter 2026 results that management said fell short of expectations, citing execution shortfalls and a cautious demand environment—particularly in North America—along with ongoing weakness in capital equipment spending. “Candidly, we are not satisfied wi
Azenta, Inc. (AZTA) Q2 2026 Earnings Call May 6, 2026 8:30 AM EDTCompany ParticipantsYvonne Perron - Vice President of Financial Planning & Analysis and...
Presentation Operator MessageOperator Greetings, and welcome to Azenta's Q2 2026 Fiscal Financial Results. [Operator Instructions] As a reminder, this conference is being recorded, Wednesday, May
Fiscal Second Quarter 2026 Financial Results © 2026 Azenta, Inc. • All rights reserved EARNINGS PRESENTATION May 6, 2026 ...
| 30d | 90d | YTD | 1y | |
|---|---|---|---|---|
| AZTA | -8.15% | -11.46% | -31.21% | -14.37% |
| XLV | +2.97% | -5.72% | -3.44% | +12.69% |
| Alpha (stock − sector) | -11.12% | -5.74% | -27.77% | -27.06% |
| Fund | Style | Shares | Value | % of Port | Change vs. last quarter | Period |
|---|---|---|---|---|---|---|
| StateStreet | passive | 1.76M | $37.24M | 0.00% | Added+1.7% | 2026-03-31 |
| DEShaw | quant | 679.2K | $14.35M | 0.01% | Added+30.6% | 2026-03-31 |
| Bridgewater | macro | 26.8K | $566.98K | 0.00% | Trimmed-44.0% | 2026-03-31 |
| FidelityFMR | fundamental | 3.5K | $74.57K | 0.00% | Trimmed-66.7% | 2026-03-31 |
| TRowePrice | fundamental | 54.8K | $1.16K | 0.00% | Added+30.4% | 2026-03-31 |
| Report Date | EPS Estimate | EPS Actual | Surprise |
|---|---|---|---|
| 2026-08-04upcoming | 0.10 | — | — |
| 2026-05-05 | 0.14 | -0.04 | -128.99% |
| 2026-02-04 | 0.13 | 0.09 | -32.98% |
| 2025-11-21 | 0.20 | 0.21 | +7.30% |
| 2025-08-05 | 0.14 | 0.19 | +39.02% |
| 2025-05-07 | 0.07 | 0.05 | -31.82% |
| 2025-02-05 | 0.06 | 0.08 | +33.33% |
| 2024-11-12 | 0.11 | 0.18 | +61.19% |
| 2024-08-06 | 0.07 | 0.16 | +134.16% |
| 2024-05-08 | 0.02 | 0.05 | +172.78% |
| 2024-02-07 | -0.03 | 0.02 | +158.82% |
| 2023-11-13 | 0.02 | 0.13 | +609.22% |
| 2023-08-08 | -0.02 | 0.13 | +699.91% |
| 2023-05-09 | -0.02 | -0.06 | -172.73% |
| 2023-02-08 | 0.10 | 0.12 | +20.00% |
| 2022-11-14 | 0.07 | 0.16 | +142.42% |